EN DE
Watch Sana Biotechnology Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sana Biotechnology Inc (SANA) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Sana Biotechnology Inc stock $1.73, price $1.88, that is 8.0% below the price, quality 26 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US7995661045

SB Sana Biotechnology Inc logo Thin data Nov 11, 2026

Sana Biotechnology Inc

SANA · US

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Fair value $1.73 · Fairly valued 
Quality 26/100 
Falling price (downtrend) 
Negative free cash flow 
Trails peers (1/5) 
Narrow moat 5/100 · thin data
Thin data 
Estimate
Watch Sana Biotechnology Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$25.88 $1.34 Fair Value $1.73 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $1.34 – $25.88 · fair‑value band $1.30 – $2.17 · the $1.88 price screens above the $1.73 fair value. As of Nov 11, 2026.

Follow Sana Biotechnology in your weekly email

Every Wednesday you see whether Sana Biotechnology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States.

Show moreShow less

It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.

The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases.

The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells.

The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018.

Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Stock analysis

Sana Biotechnology Inc (SANA) currently trades at $1.88, while our estimate is $1.73, so the stock looks roughly fairly valued today (gap 8.7%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.30 (bear) to $2.17 (bull), the price of $1.88 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Sana Biotechnology Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$244M in FY2025.

Key figures

Market cap $571M Small · EPS (TTM) $−0.5200 · Return on equity −79.5% · Return on assets (EBIT) −43.4% (5-year average) · Free cash flow −$145M · Net debt $7.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).

What moves the price

The share trades about 64% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −8%, SANA screens richer than that median.

Fair Value

Bear $1.30 Fair Value $1.73 Bull $2.17
Price $1.88 · Downside -8.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 52
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 3 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch SANA, get fair value alerts →

Compare Sana Biotechnology Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 1/3 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −8.0% · Above median
Profitability
Return on assets −58.6% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.55× · book value is mostly intangible assets ⓘGoodwill and other intangible assets (such as prices paid for past acquisitions, brands, licences or film and series rights) are larger than the equity. So we do not rank this P/B against the peer group.

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)23 · sector 1
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs SANA
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs SANA
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs SANA
argenx SE ARGX $950.95 $908.40 −4% vs SANA
CSL Limited CSL A$199.55 A$186.49 −7% vs SANA
Moderna, Inc MRNA $215.27 $135.64 −37% vs SANA
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs SANA
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs SANA
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs SANA
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs SANA

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sana Biotechnology Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sana Biotechnology Inc Fair Value". https://www.fairvalue-calculator.com/stock/SANA

Frequently asked questions

Is Sana Biotechnology Inc (SANA) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $1.73 versus a price of $1.88, about 8% lower (fairly valued).
What is the fair value of SANA?
Our estimate for Sana Biotechnology Inc is $1.73 (as of Nov 11, 2026), built from audited fundamentals. The current price: $1.88.
What is the quality score of SANA?
Sana Biotechnology Inc has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sana Biotechnology Inc (SANA)?
Our calculated price target is the estimate of $1.73 (as of Nov 11, 2026). Cautious scenario $1.30, optimistic scenario $2.17. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Sana Biotechnology Inc stock forecast for 2026?
Our estimate puts fair value at $1.73, about 8% lower versus a price of $1.88 (fairly valued). Cautious scenario $1.30, optimistic scenario $2.17. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Sana Biotechnology Inc (SANA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sana Biotechnology Inc it is $1.73 per share (as of Nov 11, 2026), against a price of $1.88.
Is Sana Biotechnology Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, SANA trades above its calculated fair value: price $1.88, fair value $1.73, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SANA?
No. The price is what the market pays today ($1.88); the fair value is what the company's own numbers justify ($1.73). For Sana Biotechnology Inc the two are $0.1500 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sana Biotechnology Inc worth?
The market values Sana Biotechnology Inc at about $571M (market capitalisation, as of Nov 11, 2026). Per share that is $1.88; our models calculate a fair value of $1.73 per share.
What do the bullish and bearish scenarios say about SANA?
Our models span a range for Sana Biotechnology Inc: cautious scenario $1.30, base $1.73, optimistic $2.17 per share (as of Nov 11, 2026, price $1.88). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sana Biotechnology Inc (SANA)?
Balance-sheet figures for Sana Biotechnology Inc (as of Nov 11, 2026): return on equity −79.5%. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is SANA from its 52-week high?
Sana Biotechnology Inc trades at $1.88, about 64% below its 52-week high of $5.18 and at the low of $1.88 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $1.73 is for.
Which stocks are comparable to Sana Biotechnology Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sana Biotechnology Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $1.88, calculated fair value $1.73 (−8%), Quality Score 26/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Sana Biotechnology Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sana Biotechnology Inc (SANA)?
The closing price on Nov 16, 2026 was $1.88. Our estimate is $1.73, about 8% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sana Biotechnology Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Sana Biotechnology Inc

How large is the market capitalisation of Sana Biotechnology Inc (SANA)?
The market capitalisation of Sana Biotechnology Inc is $571M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Sana Biotechnology Inc (SANA)?
Earnings per share at Sana Biotechnology Inc are $−0.5200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Sana Biotechnology Inc (SANA)?
The return on equity (ROE) of Sana Biotechnology Inc is −79.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sana Biotechnology Inc (SANA)?
On an EBIT basis the return on assets of Sana Biotechnology Inc is −43.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Sana Biotechnology Inc (SANA) generate?
The free cash flow of Sana Biotechnology Inc is −$145M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sana Biotechnology Inc (SANA) carry?
The net debt of Sana Biotechnology Inc is $7.0M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Sana Biotechnology Inc in the live analysis

One click puts Sana Biotechnology Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.